Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
SYRE holding history
Spyre Therapeutics, Inc. in every 13F filed by Affinity Asset Advisors, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SYRE overviewAll 13F holders of SYREFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,279,134
- Value
- $113.6M
- % of portfolio
- 5.6%
- Quarters held
- 13
- Since Q2 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,279,134 | $113.6M | 5.6% | 00.0% | Unchanged | Holders |
| Q1 2026 | 1,279,134 | $64.5M | 3.8% | −153,457−10.7% | Reduced | Holders |
| Q4 2025 | 1,432,591 | $46.9M | 3.4% | +13,292+0.9% | Added | Holders |
| Q3 2025 | 1,419,299 | $23.8M | 2.2% | +812,621+133.9% | Added | Holders |
| Q2 2025 | 606,678 | $9.08M | 1.3% | +125,000+26.0% | Added | Holders |
| Q1 2025 | 481,678 | $7.77M | 1.2% | −342,650−41.6% | Reduced | Holders |
| Q4 2024 | 824,328 | $19.2M | 3.0% | +325,908+65.4% | Added | Holders |
| Q3 2024 | 498,420 | $14.7M | 2.3% | −15,000−2.9% | Reduced | Holders |
| Q2 2024 | 513,420 | $12.1M | 1.9% | +103,420+25.2% | Added | Holders |
| Q1 2024 | 410,000 | $15.6M | 2.5% | −107,554−20.8% | Reduced | Holders |
| Q4 2023 | 517,554 | $11.1M | 2.2% | +275,257+113.6% | Added | Holders |
| Q3 2023 | 242,297 | $2.97M | 1.0% | +46,297+23.6% | AddedConverted for a 1-for-25 split | Holders |
| Q2 2023 | 4,900,000 | $2.21M | 0.9% | +4,900,000 | New | Holders |